{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-23-000032","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.410745+00:00","generated_at":"2026-06-12T15:23:19.988604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVS Health Q2 rev +10%, EPS $1.48; lowers GAAP EPS guidance to $6.53-$6.75","bullets":["Revenue $88.9B, +10.3% YoY; GAAP diluted EPS $1.48 (down from $2.29); adj EPS $2.21 (down from $2.53).","Full-year GAAP diluted EPS guidance cut to $6.53-$6.75 from $6.90-$7.12; adj EPS guidance confirmed $8.50-$8.70.","Operating income $3.23B, down $1.44B YoY; adjusted operating income $4.48B down $521M.","Completed Oak Street Health acquisition on May 2, 2023; returned $795M to shareholders via dividends in Q2.","Year-to-date cash flow from operations $13.3B; reaffirmed FY cash flow guidance $12.5B-$13.5B."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-23-000032","json":"https://secwatch.observer/filing/0000064803-23-000032.json","markdown":"https://secwatch.observer/filing/0000064803-23-000032.md","text":"https://secwatch.observer/filing/0000064803-23-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000032/0000064803-23-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000032/cvs-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T15:23:19.988604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53030e0c90388b7caa20d9f9489da2b52e1ce01e","claim":"CVS HEALTH Corp reported the three months ended June 30, 2023 results: revenue $88,921, EPS $1.48. Guidance lowered.","evidence_excerpt":"Adjusted EPS of $4.41 • Generated cash flow from operations of $13.3 billion Three Months Ended June 30, In millions, except per share amounts 2023 2022 Change Total revenues $ 88,921 $ 80,636 $ 8,285 Operating income 3,234 4,669 (1,435) Adjusted operating income (1) 4,481 5,002 (521) Diluted earnings per share $ 1.48 $ 2.29 $ (0.81) Adjusted EPS (2) $ 2.21 $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000032/0000064803-23-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$88,921"},{"label":"EPS","value":"$1.48"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5718351cb715cc39805ad69f46bf51993ecc231b","claim":"CVS HEALTH Corp reported 2023 Full-year results: EPS $6.53 to $6.75. Guidance lowered.","evidence_excerpt":"Revised GAAP diluted EPS guidance range to $6.53 to $6.75 from $6.90 to $7.12","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000032/0000064803-23-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023 Full-year"},{"label":"EPS","value":"$6.53 to $6.75"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}